Amgen announced a $650 million expansion of its biologics manufacturing facility in Juncos, Puerto Rico, aimed at increasing drug production and integrating advanced technologies. This investment is expected to create nearly 750 new jobs, including construction and highly skilled manufacturing roles.
Robert A. Bradway, Amgen’s chairman and CEO, emphasized the company’s commitment to U.S. biomanufacturing and strengthening the global supply chain. He highlighted that expanding manufacturing capacity with cutting-edge technology will enhance patient care and generate high-quality jobs, reinforcing America’s leadership in biotechnology.
Puerto Rico Governor Jenniffer González Colón praised the investment as a reflection of Amgen’s ongoing partnership with the island’s skilled workforce. She noted that the expansion will bolster U.S. supply chain security and support Puerto Rico’s development as a leading biopharmaceutical hub.
Sebastián Negrón Reichard, Puerto Rico’s Secretary of Economic Development and Commerce, underscored the island’s 60 years of biopharmaceutical expertise and infrastructure, viewing Amgen’s investment as a boost to its competitive and innovative ecosystem.
Amgen’s expansion follows a history of over $40 billion invested in U.S. manufacturing and research since the 2017 Tax Cuts and Jobs Act, with further support from the 2025 One Big Beautiful Bill Act encouraging domestic investment in science and manufacturing.
This new investment complements Amgen’s recent projects, including a $600 million science and innovation center in California and manufacturing expansions totaling $1.9 billion in Ohio and North Carolina.